Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

This randomized clinical trial determines whether flecainide dosed to therapeutic levels and added to β-blocker therapy is superior to β-blocker therapy alone for the prevention of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.

Read the full article here

Related Articles